NDAORALCAPSULE
Approved
May 2008
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
16
Data completeness
4/8 — Partial
ENTEREG (alvimopan) by Merck & Co. is μ-opioid receptor with a ki of 0. First approved in 2008.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENTEREG (alvimopan) is an oral small-molecule μ-opioid receptor antagonist approved for reducing postoperative ileus, a gastrointestinal motility impairment following abdominal surgery. It works by competitively blocking opioid receptors in the GI tract while preserving central analgesic effects, thereby counteracting opioid-induced bowel dysfunction without compromising pain relief. Alvimopan enables faster GI recovery and hospital discharge in post-surgical patients.
Peak3.3 years to LOE
ENTEREG is in peak commercial phase with moderate competitive pressure (8/10), suggesting mature market positioning and stable but not expanding brand teams.
Mechanism of Action
μ-opioid receptor with a Ki of 0.4 nM (0.2 ng/mL) and no measurable opioid-agonist effects in standard pharmacologic assays. The dissociation of [H]-alvimopan from the human μ-opioid receptor is slower than that of other opioid ligands, consistent with its higher affinity for the receptor. At…
Indications
Worked on ENTEREG at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.